Diabetes management performance improvement project : final report by Arizona Health Care Cost Containment System (Author)
 Arizona Health Care Cost Containment System 
 
 
 
 
 
DIABETES MANAGEMENT 
PERFORMANCE IMPROVEMENT PROJECT  
 
 
FINAL REPORT 
 
Prepared by the Division of Health Care Management 
October 2006 
 
 
  
Anthony D. Rodgers 
Director, AHCCCS
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
For questions or comments about this report, contact: 
Rochelle Tigner 
Quality Improvement Manager, Clinical Quality Management 
Division of Health Care Management, AHCCCS 
(602) 417-4683 
rochelle.tigner@azahcccs.gov
Arizona Health Care Cost Containment System (AHCCCS) 
 
DIABETES MANAGEMENT 
PERFORMANCE IMPROVEMENT PROJECT 
 
Final Report 
 
 
INTRODUCTION 
The Burden of Diabetes ............................................................................................. 1
What is Diabetes? ....................................................................................................... 1
The Importance of Glucose Control …....................................................................... 2
 
PROJECT METHODS 
Measurement Criteria ………………………………………………………………. 3
Population .................................................................................................................. 3
Sample Frame ............................................................................................................ 3
Measurement Periods ................................................................................................. 3
Data Sources .............................................................................................................. 4
Study Sample ………………………………………………………………………. 4
Data Collection .......................................................................................................... 4
Data Quality and Reliability ...................................................................................... 4
Study Indicators ......................................................................................................... 4
National Benchmarks ................................................................................................. 5
Performance Improvement Goals .............................................................................. 5
Intervention and Re-evaluation Process ……………………………………………. 5
 
RESULTS AND ANALYSIS 
Included Cases ........................................................................................................... 6
Hb A1c Testing .......................................................................................................... 6
Hb A1c Levels ........................................................................................................... 6
Contractor Performance …......................................................................................... 6
Data Validation Studies ……………………………………………………………. 7
 
DISCUSSION 
Overall Results ........................................................................................................... 7
Contractor Interventions ............................................................................................ 8
Conclusion ................................................................................................................. 9
 
REFERENCES 9
 
TABLES AND FIGURES 11
 
APPENDIX: METHODOLOGY AND TECHNICAL SPECIFICATIONS i
Arizona Health Care Cost Containment System (AHCCCS) 
 
DIABETES MANAGEMENT 
PERFORMANCE IMPROVEMENT PROJECT 
 
Final Report 
 
INTRODUCTION 
 
The Burden of Diabetes 
The federal Centers for Disease Control 
and Prevention (CDC) estimates that more 
than 20 million Americans age 20 years 
and older, or 9.6 percent of all people in 
this age group, have diabetes. About 1.5 
million new cases of diabetes were 
diagnosed among people 20 years and 
older in 2005.1  
 
An estimated 244,000 Arizona adults had a 
diagnosis of diabetes in 2002, the most 
recent year for which state-specific data 
are available.2 
 
Diabetes was the sixth leading cause of 
death in the United States in 2002, causing 
or contributing to at least 224,000 deaths. 3 
 
In the United States, Hispanics, blacks, 
American Indians and Alaska natives are 
twice as likely to have diabetes than non-
Hispanic whites.1  National data also show 
higher rates of diabetes among people with 
low socioeconomic status or those covered 
by Medicaid, men and people age 60 and 
older. 1,4 
 
The number of people in the United States 
with diagnosed diabetes has more than 
doubled in the last 15 years.5 The 
prevalence of diabetes in Arizona also has 
increased during that time.6 Contributing to 
this increase is the large number of “baby 
boomers” who are aging and living longer 
than previous generations. A sedentary 
lifestyle and a dramatic rise of obesity in 
the U.S. population also are increasing the 
incidence of diabetes.7
 
 
Total U.S. expenditures related to 
diabetes were approximately 
$132 billion in 2002 
 
About one out of every 10 health care 
dollars in the United States is spent on 
diabetes and its complications. Total U.S. 
expenditures related to diabetes were 
approximately $132 billion in 2002 – $92 
billion in direct medical costs and another 
$40 billion in indirect costs because of 
missed work days or other losses in 
productivity.9 At least 4 million 
hospitalizations and more than 26 million 
outpatient visits annually in the U.S. are 
associated with diabetes.8,10 
 
What is Diabetes? 
Diabetes mellitus is a group of chronic 
diseases characterized by high levels of 
blood glucose, which occur when the body 
does not properly produce or use insulin. 
Insulin is a hormone that is needed to 
convert carbohydrates into glucose, a 
simple sugar that is a primary source of 
energy. Both genetics and lifestyle, such as 
obesity and lack of exercise, are associated 
with the disease.3
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There are several types of diabetes:3 
• Type 1 diabetes accounts for 5 to 10 
percent of all diagnosed cases, and occurs 
when the cells that produce insulin are 
destroyed. Type 1 diabetes usually begins 
in childhood or adolescence, and has been 
called juvenile-onset diabetes. 
• Type 2 diabetes, which accounts for 90 
to 95 percent of diagnosed cases, occurs as 
the body develops insulin resistance or the 
pancreas loses the ability to produce 
insulin. Type 2 is associated with both 
genetic and behavioral factors, including 
age, obesity, physical inactivity, family 
history and race or ethnicity. Normally 
seen in adults, type 2 diabetes is on the rise 
in children and young adults, particularly 
among American Indians, African 
Americans and Hispanic or Latino 
Americans. 
• Gestational diabetes, which is 
diagnosed in about 4 percent of women 
during pregnancy, and may be manifested 
later as type 2 diabetes. 
• Other types of diabetes result from 
specific genetic conditions, drugs, 
malnutrition, infections and other illnesses. 
These types account for 1 percent to 5 
percent of diagnosed cases. 
 
 
Up to 70 percent of people with 
diabetes have mild to severe 
forms of nervous system damage 
 
 
With diabetes, sustained high blood sugars 
result in microvascular complications; that 
is, damage to the very fine blood vessels of 
the eyes, peripheral nerves and kidneys. 
Diabetic retinopathy (damage to the retina 
of the eye) causes 12,000 to 24,000 new 
cases of blindness each year. Up to 70 
percent of people with diabetes have mild 
to severe forms of nervous system damage, 
including impaired sensation or pain in the 
feet or hands, slowed digestion of food, 
carpal tunnel syndrome and other nerve 
problems.3
 
Macrovascular complications include 
coronary and peripheral artery disease, 
which may lead to heart attack or stroke, 
and amputation. As with many diseases, 
other conditions (known as comorbid 
conditions) may be present with diabetes. 
 
The Importance of Glucose Control 
Despite its deadly effects, diabetes can be 
controlled. Many complications of the 
disease can be prevented or reduced with 
early detection, improved care and better 
education of patients in self-management 
techniques.5,11
 
Control of hyperglycemia (increased blood 
sugar) is critical to reducing both the 
incidence and progression of complications 
associated with diabetes. Physicians utilize 
a glycosylated hemoglobin, or Hb A1c, test 
to monitor patients’ blood glucose levels. 
This test indicates a person’s average 
glucose level over a two- to three-month 
period by measuring the amount of glucose 
that has bonded with hemoglobin in the 
body’s red blood cells.
 
Studies in the United States and abroad 
have shown that improved glycemic 
control benefits people with either type 1 
or type 2 diabetes. In general, for every 
percentage point decrease in Hb A1c levels, 
the risk of developing microvascular 
complications is reduced by 35 to 40 
percent. 3,12,13 
 
This performance improvement project 
(PIP) was initiated in 2002. Its purpose 
was to increase the rate of Hb A1c testing 
among adults with diabetes who were 
enrolled with the Arizona Health Care Cost 
Containment System (AHCCCS) and to 
reduce the proportion of those members 
whose blood glucose was poorly 
controlled. 
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PROJECT METHODS 
 
Measurement Criteria 
AHCCCS used Health Plan Employer Data 
and Information Set (HEDIS) 
specifications from the National 
Committee for Quality Assurance (NCQA) 
as a guideline for measurement of diabetes 
management. HEDIS methodology 
includes six indicators of comprehensive 
diabetes care. For purposes of this PIP, 
AHCCCS chose to focus on two critical 
indicators: Hb A1c testing and Hb A1c 
levels.  
 
It should be noted that, while the HEDIS 
indicators are based on clinical 
considerations, they are not the same as 
treatment guidelines. HEDIS measurement 
criteria differ from clinical standards, such 
as those set forth by the American 
Diabetes Association (ADA) and the 
American Association of Clinical 
Endocrinologists (AACE), for frequency 
of Hb A1c testing and optimum laboratory 
values. However, HEDIS specifications 
provide a standardized method for valid 
and reliable measurements of these 
services, and results can be compared with 
data reported to NCQA by other health 
care organizations using this methodology. 
 
HEDIS methodology was used to establish 
baseline rates for each indicator, and to 
remeasure rates after interventions to 
improve utilization of services were 
implemented. 
 
Population 
The population included in each 
measurement consisted of members ages 
18 to 75 who were diagnosed with type 1 
or type 2 diabetes, as identified by HEDIS 
criteria. 
Tribal and fee-for-service members were 
excluded from this study due to the 
inability to accurately collect complete 
data on these populations. Often these 
members seek medical care outside of the 
AHCCCS system using their Indian Health 
Service or Medicare benefits. Therefore, 
information on Hb A1c testing is not 
available from AHCCCS encounter data. 
 
Sample Frame 
The sample frame consisted of members 
who: 
• were ages 18 through 75 years as of 
September 30 of the measurement period, 
• were continuously enrolled with one 
AHCCCS-contracted health plan 
(Contractor), with no more than one gap in 
enrollment, not exceeding 31 days, as of 
September 30, and 
• had a diagnosis of type 1 or type 2 
diabetes in the measurement period or the 
year prior to the measurement period. 
 
Members were identified as having type 1 
or type 2 diabetes by either pharmacy or 
encounter data (records of claims paid for 
covered services). For example, a member 
was identified as having diabetes if he or 
she had one face-to-face encounter with a 
diagnosis of diabetes in an acute inpatient 
or emergency room setting during the 
measurement period or the previous year. 
 
Measurement Periods 
Multiple measurements were conducted to 
determine whether contracted health plans 
(Contractors) demonstrated improvement 
over their baseline rates and at least 
maintained that level of performance for an 
additional year. Contractors were allowed 
a year between the baseline and first 
remeasurement to implement interventions 
to improve Hb A1c testing and levels. 
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Measurements for this PIP were based on 
AHCCCS contract years, as follows: 
• Baseline - October 1, 2000, through 
September 30, 2001 
• First Remeasurement - October 1, 
2002, through September 30, 2003 
• Second Remeasurement - October 1, 
2003, through September 30, 2004 
 
AHCCCS conducted an additional 
measurement of performance by one 
Contractor that did not previously 
demonstrate sustained improvement, which 
included the contract year October 1, 2004, 
through September 30, 2005. 
 
Data Sources 
AHCCCS uses a statewide, automated 
managed care data system known as the 
Prepaid Medical Management Information 
System (PMMIS). AHCCCS enrollment 
and encounter data contained in PMMIS 
were used to select sample members for 
this study and to collect data on any Hb 
A1c tests provided to sample members 
during the measurement period. These data 
were supplemented by data collected by 
Contractors from their claims systems 
and/or medical and laboratory records. 
 
Study Sample 
For each measurement, AHCCCS selected 
a sample stratified by program type (i.e., 
Acute-care health plans vs. long-term care 
plans) and individual Contractor. A 
statistical software program was used to 
select a representative, random sample, 
using a 95-percent confidence level and a 
confidence interval of +/-5 percent. Based 
on prior studies, an over sampling rate of 
10 percent was utilized. 
 
Data Collection 
AHCCCS initially collected data on Hb 
A1c testing from its encounter system 
(laboratory values for Hb A1c levels were 
not available from encounter data). When 
AHCCCS did not find encounters for Hb 
A1c tests for sample members within the 
measurement period, it required 
Contractors to collect data for those 
members. Contractors collected additional 
data for tests performed, as well as Hb A1c 
levels for all sample members tested 
during the measurement period. This 
information was entered by Contractor 
staff into a standardized electronic data 
collection tool, according to detailed 
instructions from AHCCCS.  
 
Data Quality and Reliability 
AHCCCS conducts studies to evaluate the 
accuracy of encounter data. Based on the 
most recent data validation study, more 
than 90 percent of all encounters in 
PMMIS are accurate when compared with 
the corresponding medical records. 
 
Contractors were required to submit 
information to validate any additional data 
collected (e.g., hard copies of the 
appropriate sections of medical records or 
electronic laboratory data) with their 
completed electronic data collection tools. 
 
Study Indicators 
 
Hb A1c testing — This indicator measured 
the percent of members who had one or 
more Hb A1c tests during the measurement 
period. 
 
Hb A1c level — This indicator measured 
the percent of members whose most recent 
Hb A1c tests during the measurement 
period showed blood-glucose levels greater 
than 9.5 percent (the level at which HEDIS 
criteria indicated “poor control” of blood 
glucose when this PIP was initiated; the 
HEDIS level for poor control has since 
been lowered). According to HEDIS 
criteria, if there was no documentation of a 
test performed during the measurement 
period or if a laboratory level for a test was 
not documented, the member was 
considered to have poor glucose control. 
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National Benchmarks 
AHCCCS utilized as benchmarks for these 
indicators the most recent national HEDIS 
averages for Medicaid health plans that 
were available at the time the baseline 
measurement was collected in 2002. The 
Medicaid mean (average) for annual Hb 
A1c testing was 68.5 percent. The mean for 
poor control of blood-glucose for Medicaid 
plans was 54.9 percent. (The current 
Medicaid averages, based on calendar year 
2004 data, are 76.0 percent for Hb A1c 
testing and 48.6 percent for poor control.). 
 
Performance Improvement Goals 
Through this performance improvement 
project, all Contractors were expected to 
increase their rates of annual Hb A1c 
testing and reduce the proportion of 
members with poorly controlled diabetes 
(those with Hb A1c levels greater than 9.5 
percent.). 
 
Improvement was determined according to 
whether Contractors “narrowed the gap” 
between their baseline rates and the 
benchmark, as follows: 
• When a Contractor’s baseline rate for 
either indicator was below the AHCCCS 
overall average for the baseline 
measurement, it must have improved its 
rate to meet or exceed the AHCCCS 
baseline average, and the change must 
have been statistically significant (p<.05). 
• When the Contractor’s baseline rate 
was above the AHCCCS overall average, 
but below the NCQA average at baseline, 
it must have met or exceeded the NCQA 
rate on the first remeasurement, and the 
change must have been statistically 
significant. 
• When the Contractor achieved a rate 
for the first remeasurement that was at or 
above the NCQA benchmark. 
 
Contractors that demonstrated 
improvement from the baseline to first 
remeasurement or achieved the benchmark 
rate must have at least maintained that 
level of performance for the second 
remeasurement to meet the AHCCCS 
requirement of “sustained improvement” 
for PIPs. Contractors that achieved 
demonstrable and sustained improvement 
in the second remeasurement were 
considered to have completed this PIP. 
Any Contractor who did not show 
demonstrable and sustained improvement 
by the second remeasurement was required 
to continue the project until it met that 
standard. 
 
Intervention and Re-evaluation Process 
In addition to the baseline measurement 
and remeasurements of performance 
conducted by AHCCCS, the agency 
provided technical assistance to 
Contractors on barriers to Hb A1c testing 
and strategies to improve care. This 
included researching and providing 
information on evidence-based practices to 
improve diabetes management, providing 
educational presentations at regular 
AHCCCS meetings with Contractors, and 
advising them of other educational 
opportunities and resources. 
 
Contractors began implementing 
interventions to improve their rates in CYE 
2003, after the baseline measurement was 
collected and analyzed by AHCCCS. After 
the first remeasurement, Contractors 
reported to AHCCCS when specific 
interventions were implemented and an 
evaluation of their effectiveness. If a 
Contractor did not show improvement over 
its baseline rates, it was expected to revise 
or enhance existing strategies and/or add 
new interventions. 
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RESULTS AND ANALYSIS 
 
Included Cases 
The baseline measurement included 2,945 
members with diabetes who were enrolled 
with Acute-care Contractors or Arizona 
Long Term Care System (ALTCS) 
Contractors. This total included members 
with two health plans that no longer 
contract with AHCCCS, CIGNA 
Community Choice and Family Health 
Plan of Northeastern Arizona. Data for 
these health plans were subsequently 
excluded from the PIP, leaving a baseline 
measurement that consisted of 2,673 
sample members. The first and second 
remeasurements included 3,248 members 
and 3,360 members, respectively, who 
were enrolled with 15 Contractors. 
 
Hb A1c Testing 
Overall, the proportion of members who 
had at least one Hb A1c test during the 
measurement period increased from the 
baseline measurement to the first 
remeasurement (p<.001), as shown in 
Table 1. After exclusion of members from 
the two health plans, the overall proportion 
of members who received an Hb A1c test 
during the baseline measurement period 
was 60.8 percent, compared with the 
overall rate for the first remeasurement of 
76.3 percent.  
 
The overall rate further improved in the 
second remeasurement, with a rate of 79.5 
percent (p<.001), as shown in Table 2. 
 
Hb A1c Levels (Poor Control) 
Overall, 49.4 percent of members in the 
revised baseline measurement (after 
exclusion of the two health plans’ data) 
were considered to have poor control of 
blood-glucose levels. The first 
remeasurement showed a reduction in the 
rate of poorly controlled levels, to 37.4 
percent (p<.001), as shown in Table 3. The 
overall rate of poor control further 
improved in the second remeasurement, 
with a rate of 30.9 percent (p<.001), as 
shown in Table 4. 
 
AHCCCS Diabetes Care PIP,
Overall Baseline and 
Remeasurement Rates
0
20
40
60
80
100
Testing Poor Control*
Baseline
Remeas 1
Remeas 2
 
 
* Note: Lower rates for this indicator are better. 
 
Rates for both indicators also were 
analyzed by program type (Acute-care or 
ALTCS) and by individual Contractors 
(Tables 1 through 4). 
 
Contractor Performance 
From baseline to the first remeasurement, 
all but one Contractor, Evercare Select, 
showed statistically significant 
improvement and/or achieved the 
benchmark level of performance (the 
NCQA Medicaid average of 68.5 percent) 
for Hb A1c testing. The number of plans 
exceeding the NCQA benchmark increased 
from five (33.3 percent) in the baseline 
measurement to 11 ( 73.3 percent) in the 
first remeasurement, as shown in Figures 1 
and 2. 
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In the second remeasurement, all 
Contractors sustained (i.e., did not show a 
statistically significant decrease) or 
improved their levels of performance in Hb 
A1c testing. Evercare Select, which showed 
no statistically significant change from the 
baseline to first remeasurement (p=.243), 
demonstrated a statistically significant 
increase in its rate between the first and 
second remeasurements (p=.046). 
 
For poor control of Hb A1c levels, all 
Contractors showed statistically significant 
improvement and/or achieved the 
benchmark (i.e., under the NCQA 
Medicaid average of 54.9 percent) from 
the baseline to first remeasurement. The 
number of plans with rates better than the 
NCQA benchmark increased from nine 
(60.0 percent) in the baseline measurement 
to 15 (100.0%) in the first remeasurement, 
as shown in Figures 3 and 4. All 
Contractors maintained or further 
improved their levels of performance in the 
second remeasurement. 
 
In order to verify that Evercare Select had 
sustained or improved its level of HbA1c 
testing, another remeasurement was 
conducted for this Contractor only. As 
shown in Table 5A, Evercare Select further 
improved its level of Hb A1c testing during 
the third remeasurement, to 77.2 percent 
from 66.9 percent in the second 
remeasurement (p<.001). The Contractor 
sustained its previous improvement in the 
indicator of poor control (Table 5B). 
 
Data Validation Studies 
AHCCCS validated data submitted by 
Contractors for the first remeasurement of 
this project. A double-blind validation 
study was performed by AHCCCS in May 
2005, matching the medical record or 
laboratory data with data on the 
Contractor’s electronic file. The results of 
this validation showed a Kappa agreement 
of 77.0 percent for Hb A1c testing data and 
84.0 percent for Hb A1c levels, for a total 
agreement of 82.6 percent, as shown in 
Table 6.  
 
Data also were validated by individual 
Contractor, as shown in Table 7. One 
Contractor, Health Choice Arizona, did not 
provide adequate documentation to 
validate its data. Excluding data for this 
Contractor, the overall Kappa agreement 
was 88.8 percent for Hb A1c testing and 
91.7 percent for Hb A1c levels, for a total 
agreement of 91.5 percent (Table 6). 
 
Because data for Health Choice Arizona 
could not be validated for the first 
remeasurement, AHCCCS conducted a 
validation study on data collected by this 
Contractor for the second remeasurement. 
As shown in Table 8, the total Kappa 
agreement for Health Choice was 97.9 
percent. The Kappa agreement was 96.8 
percent for Hb A1c testing and 97.5 percent 
for Hb A1c levels. 
 
 
DISCUSSION 
Overall Results 
This Performance Improvement Project 
resulted in improvements in both HbA1c 
testing and the proportion of members with 
poorly controlled blood glucose. With 
nearly 80 percent of sample members 
receiving at least one Hb A1c test in the 
second remeasurement period, less than 
one-third had Hb A1c levels greater than 
9.5 percent (including those members who 
did not have a test or documentation of the 
laboratory value). These improvements can 
be associated with interventions 
implemented by Contractors during the 
project period, as well as ongoing technical 
assistance provided by AHCCCS. 
 7
The American Diabetes Association 
recommends that people with diabetes 
maintain an Hb A1c level of less than 7.0 
percent.14 Among eight ALTCS 
Contractors, members enrolled with seven 
plans had median Hb A1c levels of less 
than 7.0 percent in the second 
remeasurement (Table 4). The median 
level among all members at the end of the 
project was 7.0 percent. 
 
 
 
 
 
The American Diabetes 
Association recommends 
an HbA1c level 
of less than 7.0 percent 
 
 
Contractor Interventions 
After completing analysis of baseline data, 
AHCCCS identified barriers to Hb A1c 
testing and control, as well as successful 
strategies for increasing the rate of testing. 
This research and potential interventions 
were discussed in the report on the 
baseline measurement for this PIP, 
published by AHCCCS in 2003.  
 
In general, diabetes is difficult to treat 
because of the involvement of many body 
systems, requiring patients to adhere to 
daily and sometimes complex interventions 
to control the disease. Controlling blood 
glucose involves following a careful diet 
and exercise program, losing excess 
weight, and taking insulin and/or oral 
medication. Many people with diabetes 
face difficulty in altering their lifestyles to 
accommodate all these measures. 
 
Because diabetes is frequently an 
asymptomatic disease, patients may not 
adhere to treatment regimens or utilize 
preventive-care services such as regular 
blood-glucose testing.12 Patients’ 
socioeconomic status also may pose a 
barrier to use of preventive-care services. 
Lower levels of education are associated 
with patients not adhering to 
recommendations for diabetes self 
management. This likely is related to a 
lack of understandable or relevant patient 
education materials.13,14  
 
Physicians also face barriers in ensuring 
that patients receive preventive-care 
services and have adequately controlled 
glucose levels. Common physician barriers 
include confusion caused by differing 
recommendations regarding testing and 
treatment, the need for frequent monitoring 
and medication adjustments to achieve 
treatment goals, and time limitations.11,13  
 
Contractors also evaluated their baseline 
data and developed or enhanced existing 
activities to improve Hb A1c testing and 
levels. Based on this research and analysis, 
health plans implemented interventions 
that included: 
• Distribution of clinical practice 
guidelines for diabetes care to primary care 
practitioners (PCPs) and other providers, 
such as nursing and assisted living 
facilities 
• Providing clinical tools to PCP offices 
and nursing facilities, such as a diabetes 
flow sheet, which is placed in a member’s 
medical chart as a reminder to perform Hb 
A1c testing and other preventive-care 
services 
• Utilizing disease management or case 
management staff to contact members with 
diabetes to ensure they have Hb A1c tests 
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• Implementing methods to better 
identify members with diabetes in order to 
facilitate tracking and follow up 
• Monitoring Hb A1c testing through 
chart reviews or claims reports, and 
providing feedback to PCPs whose 
diabetic members did not have tests 
• Regularly informing health plan case 
managers, PCPs and other providers of the 
health plan’s overall results under this PIP 
• Regularly providing information to 
members with diabetes, to help ensure they 
receive appropriate tests as needed 
• Use of diabetes educators and referral 
to diabetes education classes to help 
members better understand and participate 
in managing their disease 
 
Table 9 provides more information about 
Contractors’ specific interventions under 
this PIP. 
 
Conclusion 
Contractors have submitted final reports on 
this PIP to AHCCCS, chronicling their 
interventions and evaluating the success of 
this project as it relates to their members. 
All Contractors reported that effective 
interventions will be ongoing. 
 
One ALTCS Contractor, in its final report, 
stated that it “has been literally bombarding 
members and providers with information 
about diabetes. (Contractor staff feel) that 
there is a direct correlation between our 
educational interventions and the steady, 
sustained improvement in both the Hb A1c 
testing indicator and the poor Hb A1c 
control indicator.” 
 
It should be noted that the AHCCCS 
overall rates of Hb A1c testing and poor 
control as of the second remeasurement 
(CYE 2004) are better than the current 
HEDIS means. The overall AHCCCS rate 
of 79.5 percent for Hb A1c testing exceeds 
the HEDIS 2005 mean of 76.0 percent for 
Medicaid plans nationally. The overall 
AHCCCS rate of 30.9 percent for poor 
control places the Arizona Medicaid 
program in the top 10 percent of Medicaid 
plans nationally, and is equivalent to the 
mean for commercial health plans. 
 
AHCCCS Overall Rates vs. HEDIS Means 
Measure 
AHCCCS 
Rate, 
2004 
Medicaid 
Mean, 
2005 
Commercial 
Mean, 
2005 
Hb A1c 
Testing 79.5 76.0% 86.5% 
Poor 
Control* 30.9 50.1% 30.7% 
* Note: Lower rates for this indicator are better. 
 
Finally, while this project measured 
whether members received a minimum of 
one Hb A1c test annually according to 
HEDIS criteria, clinical practice guidelines 
recommend Hb A1c testing at least twice a 
year for patients who have stable glycemic 
control and quarterly for patients who are 
not meeting glycemic goals. To further 
improve care and health outcomes for 
members with diabetes, Contractors should 
continue to focus on ensuring that 
members with diabetes receive Hb A1c 
tests and other preventive-care services at 
the recommended intervals. 
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Contractor
Included 
Cases
Number 
Receiving Hb 
A1c Test
Percent Receiving 
Hb A1c Test Relative Change 
Significance 
Level
APIPA 360 297 82.5% 204.9% p<.001
340 92 27.1%
Health Choice Arizona 298 248 83.2% 7.2% p=.098
255 198 77.6%
Maricopa Health Plan 269 225 83.6% 2.5% p=.542
267 218 81.6%
Mercy Care Plan 359 283 78.8% 19.4% p<.001
332 219 66.0%
Phoenix Health Plan/ 
Community Connection 309 202 65.4% 37.4% p<.001
252 120 47.6%
Pima Health System 234 188 80.3% 12.2% p=.035
190 136 71.6%
University Family Care 243 198 81.5% -2.6% p=.553
178 149 83.7%
ACUTE Subtotal 2072 1641 79.2% 26.9% p<.001
1814 1132 62.4%
Cochise Health Systems 83 67 80.7% 29.5% p=.010
77 48 62.3%
Evercare Select 167 84 50.3% -11.8% p=.243
135 77 57.0%
Maricopa LTC 217 173 79.7% 25.3% p<.001
253 161 63.6%
Mercy Care LTC 185 125 67.6% 52.0% p=.049
18 8 44.4%
Pima Health System LTC 201 155 77.1% 8.6% p=.200
145 103 71.0%
Pinal/Gila County LTC 74 54 73.0% 86.5% p<.001
46 18 39.1%
Yavapai County LTC 78 50 64.1% 43.0% p=.025
58 26 44.8%
DES/DDD 171 128 74.9% 86.3% p<.001
127 51 40.2%
ALTCS Subtotal 1176 836 71.1% 24.1% p<.001
859 492 57.3%
OVERALL 3248 2477 76.3% 25.5% p<.001
2673 1624 60.8%
Notes: 
(2) Significance levels in bold indicate statistically significant change
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(1) Shaded rows reflect results of the baseline measurement (October 1, 2000, through September 30, 2001).
TABLE 1
AHCCCS Diabetes Management Performance Improvement Project
Members Receiving Hb A1c Tests, by Contractor
First Remeasurement (CYE 2003) compared with Baseline Measurement (CYE 2001)
Contractor
Included 
Cases
Number 
Receiving Hb 
A1c Test
Percent Receiving 
Hb A1c Test Relative Change 
Significance 
Level
APIPA 352 300 85.2% 3.3% p=.323
360 297 82.5%
Health Choice Arizona 304 260 85.5% 2.8% p=.436
298 248 83.2%
Maricopa Health Plan 271 220 81.2% -2.9% p=.452
269 225 83.6%
Mercy Care Plan 348 289 83.0% 5.3% p=.154
359 283 78.8%
Plan/Community 299 200 66.9% 2.3% p=.693
309 202 65.4%
Pima Health System 230 177 77.0% -4.2% p=.373
234 188 80.3%
University Family Care 205 176 85.9% 5.4% p=.214
243 198 81.5%
ACUTE Subtotal 2009 1622 80.7% 1.9% p=.220
2072 1641 79.2%
Cochise Health Systems 86 76 88.4% 9.5% p=.168
83 67 80.7%
Evercare Select 184 112 60.9% 21.1% p=.046
167 84 50.3%
Maricopa LTC 252 207 82.1% 3.0% p=.505
217 173 79.7%
Mercy Care LTC 229 176 76.9% 13.8% p=.035
185 125 67.6%
Pima Health System LTC 212 160 75.5% -2.1% p=.695
201 155 77.1%
Pinal/Gila County LTC 102 89 87.3% 19.6% p=.017
74 54 73.0%
Yavapai County LTC 89 65 73.0% 13.9% p=.214
78 50 64.1%
DES/DDD 197 165 83.8% 11.9% p=.034
171 128 74.9%
ALTCS Subtotal 1351 1050 77.7% 9.3% p<.001
1176 836 71.1%
OVERALL 3360 2672 79.5% 4.3% p=.001
3248 2477 76.3%
Notes: 
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(1) Shaded rows reflect results of the first remeasurement (October 1, 2002, through September 30, 2003.
(2) Significance levels in bold indicate statistically significant change
TABLE 2
AHCCCS Diabetes Management Performance Improvement Project
Members Receiving Hb A1c Tests, by Contractor
Second Remeasurement (CYE 2004) compared with First Remeasurement (CYE 2003)
Contractor
Included 
Cases
Number with 
Hb A1c     
Level >9.5%
Percent with 
Hb A1c      
Level >9.5%
Median        
Hb A1c Level
Relative 
Change in    
Levels >9.5%
Significance 
Level
APIPA 360 118 32.8% 7.3 (6.3,8.9) -59.0% p=.109
340 272 80.0% 7.9 (6.7,9.8)
Health Choice 298 102 34.2% 7.4 (6.3,9.1) -9.2% p=.022
255 96 37.6% 7.2 (6.3,9.1)
Maricopa Health Plan 269 103 38.3% 7.9 (6.9,9.7) 12.4% p=.254
267 91 34.1% 7.2 (6,9)
Mercy Care 359 117 32.6% 7.0(6.2,8.3) -24.3% p=.657
332 143 43.1% 7.2(6.3,8.4)
Phoenix Health Plan/     
Community Connection 309 164 53.1% 7.6 (6.4,9.7) -15.3% p=.104
252 158 62.7% 7.7 (6.6,9.3)
Pima Health System 234 87 37.2% 7.5 (6.4,9.3) -8.2% p=.886
190 77 40.5% 7.2 (6.1,8.9)
University Family Care 243 90 37.0% 7.3 (6.5,9.2) 2.9% p=.197
178 64 36.0% 7.9 (6.9,9.4)
ACUTE Subtotal 2072 781 37.7% 7.4 (6.4,9.2) -24.1% p=.002
1814 901 49.7% 7.4 (6.3,9.1)
Cochise Health Systems 83 20 24.1% 6.7 (5.7,7.6) -47.0% p=.286
77 35 45.5% 6.6 (5.6,7.7)
Evercare Select 167 91 54.5% 6.7(6.2,7.8) 9.9% p=.001
135 67 49.6% 7.0(6,8.6)
Maricopa LTC 217 69 31.8% 7.3 (6.2,8.6) -27.6% p=.181
253 111 43.9% 6.6(5.6,8)
Mercy Care LTC 185 74 40.0% 6.8 (6.0,8.4) -28.0% p=.022
18 10 55.6% 6.9 (6.1,7.5)
Pima Health System LTC 201 61 30.3% 6.9 (5.9,8.2) -17.2% p=.889
145 53 36.6% 6.7 (6,8.3)
Pinal/Gila County LTC 74 24 32.4% 6.8 (6.0,7.9) -46.8% p=.143
46 28 60.9% 7.5 (6,8.6)
Yavapai County LTC 78 33 42.3% 6.9 (6.0,8.4) -29.9% p=.401
58 35 60.3% 7.9 (6.7,9)
DES/DDD 171 61 35.7% 6.5 (5.7,7.6) -44.0% p=.002
127 81 63.8% 6.3 (5.6,8)
ALTCS Subtotal 1176 433 36.8% 6.9 (6.0,8.2) -24.7% p<.001
859 420 48.9% 6.9 (6.0,8.2)
OVERALL 3248 1214 37.4% 7.2(6.2,8.8) -24.4% p<.001
2673 1321 49.4% 7.2(6.2,8.8)
Notes:
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TABLE 3
AHCCCS Diabetes Management Performance Improvement Project
Members with Poorly Controlled Hb A1c Levels, by Contractor
First Remeasurement (CYE 2003) compared with Baseline Measurement (CYE 2001)
(1) Shaded rows reflect results of the first remeasurement  (October 1, 2002, through September 30, 2003).
(2) Significance levels in bold indicate statistically significant change.
(3) Lower rates for this indicator are better.
(4)  Numbers in parentheses in Median Level column represent interquartile ranges (25th and 75th percentile) when exhibited on a Bell 
curve.
Contractor
Included 
Cases
Number with 
Hb A1c     
Level >9.5%
Percent with 
Hb A1c      
Level >9.5%
Median        
Hb A1c Level
Relative 
Change in    
Levels >9.5%
Significance 
Level
APIPA 352 96 27.3% 7.1(6.25,8.4) -16.8% p=.109
360 118 32.8% 7.3 (6.3,8.9)
Health Choice 304 78 25.7% 7.0(6.2,8.4) -24.9% p=.022
298 102 34.2% 7.4 (6.3,9.1)
Maricopa Health Plan 271 91 33.6% 7.4(6.5,9.0) -12.3% p=.254
269 103 38.3% 7.9 (6.9,9.7)
Mercy Care 348 108 31.0% 7.0(6.2,8.35) -4.9% p=.657
359 117 32.6% 7.0(6.2,8.3)
Community Connection 299 139 46.5% 7.0(6.2,8.5) -12.4% p=.104
309 164 53.1% 7.6 (6.4,9.7)
Pima Health System 230 87 37.8% 7.3(6.2,8.75) 1.6% p=.886
234 87 37.2% 7.5 (6.4,9.3)
University Family Care 205 64 31.2% 7.5(6.4,9.0) -15.7% p=.197
243 90 37.0% 7.3 (6.5,9.2)
ACUTE Subtotal 2009 663 33.0% 7.1(6.3,8.6) -12.5% p=.002
2072 781 37.7% 7.4 (6.4,9.2)
Cochise Health Systems 86 15 17.4% 6.85 (6.1,8.08) -27.8% p=.286
83 20 24.1% 6.7 (5.7,7.6)
Evercare Select 184 68 37.0% 6.5(6.0,7.5) -32.1% p=.001
167 91 54.5% 6.7(6.2,7.8)
Maricopa LTC 252 66 26.2% 7.0 (6.2,8.2) -17.6% p=.181
217 69 31.8% 7.3 (6.2,8.6)
Mercy Care LTC 229 67 29.3% 6.8 (6.0,8.3) -26.8% p=.022
185 74 40.0% 6.8 (6.0,8.4)
Pima Health System LTC 212 63 29.7% 6.7 (5.9,7.8) -2.0% p=.889
201 61 30.3% 6.9 (5.9,8.2)
Pinal/Gila County LTC 102 23 22.5% 6.9 (6.1,8.0) -30.6% p=.143
74 24 32.4% 6.8 (6.0,7.9)
Yavapai County LTC 89 32 36.0% 6.9(6.2,7.6) -14.9% p=.401
78 33 42.3% 6.9 (6.0,8.4)
DES/DDD 197 42 21.3% 6.3(5.8,7.3) -40.3% p=.002
171 61 35.7% 6.5 (5.7,7.6)
ALTCS Subtotal 1351 376 27.8% 6.8 (6.1,8.0) -24.5% p<.001
1176 433 36.8% 6.9 (6.0,8.2)
OVERALL 3360 1039 30.9% 7.0(6.2,8.3) -17.3% p<.001
3248 1214 37.4% 7.2(6.2,8.8)
Notes:
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TABLE 4
AHCCCS Diabetes Management Performance Improvement Project
Members with Poorly Controlled Hb A1c Levels, by Contractor
Second Remeasurement (CYE 2004) compared with First Remeasurement (CYE 2003)
(1) Shaded rows reflect results of the first remeasurement  (October 1, 2002, through September 30, 2003).
(2) Significance levels in bold indicate statistically significant change.
(3) Lower rates for this indicator are better.
(4)  Numbers in parentheses in Median Level column represent interquartile ranges (25th and 75th percentile) when exhibited on a Bell 
curve.




Contractor
Included 
Cases
Number Receiving 
Hb A1c Test
Percent 
Receiving Hb 
A1c Test Relative Change
Significance 
Level
Evercare Select 215 166 77.2% 26.8% p<.001
184 112 60.9%
Contractor
Included 
Cases
Number with      
Hb A1c Level 
>9.5%
Percent with     
Hb A1c Level 
>9.5%
Relative Change 
in Levels >9.5%
Significance 
Level
Evercare Select 215 96 44.7% 20.8% p=.119
184 68 37.0% 6.5(6.0,7.5)
Notes: 
TABLE 5B
AHCCCS Diabetes Management Performance Improvement Project
Members with Poorly Controlled Hb A1c Levels
TABLE 5A
AHCCCS Diabetes Management Performance Improvement Project
Members Receiving Hb A1c Tests
Third Remeasurement (CYE 2005) compared with Second Remeasurement (CYE 2004)
Third Remeasurement (CYE 2005) compared with Second Remeasurement (CYE 2004)
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(1) Shaded rows reflect results of the second remeasurement (October 1, 2003, through September 30, 2004).
(2) Significance level in bold indicates statistically significant change.
Over Under
Hb A1c Test 1016 911 105 115 10 77.0%
Poorly Controlled 505 589 -84 10 94 84.0%
Total 1521 1500 21 125 104 82.6%
Hb A1c Test 925 891 34 44 10 88.8%
Poorly Controlled 472 501 -29 10 39 91.7%
Total 1397 1392 5 54 49 91.5%
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TABLE 6
First Remeasurement Period: October 1, 2002, through September 30, 2003
Data Validation Results, All Contractors
AHCCCS Diabetes Management Performance Improvement Project
Excluding Health Choice Arizona
% Kappa 
Agreement
Original 
Abstraction
AHCCCS 
Results Difference
Critical Errors
Over Under
Hb A1c Test 84 83 1 1 0 96.5%
Poorly Controlled 44 45 -1 0 1 98.0%
Total 128 128 0 1 1 97.9%
Hb A1c Test 75 74 1 1 0 97.1%
Poorly Controlled 42 43 -1 0 1 97.9%
Total 117 117 0 1 1 97.8%
Hb A1c Test 90 75 15 15 0 65.4%
Poorly Controlled 43 54 -11 0 11 80.1%
Total 133 129 4 15 11 75.8%
Hb A1c Test 72 68 4 4 0 91.6%
Poorly Controlled 58 61 -3 0 3 94.3%
Total 130 129 1 4 3 93.0%
Hb A1c Test 91 91 0 0 0 100.0%
Poorly Controlled 34 34 0 0 0 100.0%
Total 125 125 0 0 0 100.0%
Hb A1c Test 79 79 0 0 0 100.0%
Poorly Controlled 38 39 -1 0 1 97.9%
Total 117 118 -1 0 1 98.9%
Hb A1c Test 91 20 71 71 0 7.0%
Poorly Controlled 33 88 -55 0 55 16.3%
Total 124 108 16 71 55 -20.6%
Hb A1c Test 50 50 0 0 0 100.0%
Poorly Controlled 11 11 0 0 0 100.0%
Total 29 61 0 0 0 100.0%
Hb A1c Test 62 61 1 6 5 67.7%
Poorly Controlled 29 31 -2 3 5 79.4%
Total 91 92 -1 9 10 77.5%
Hb A1c Test 71 70 1 4 3 78.0%
Poorly Controlled 26 26 0 5 5 73.1%
Total 97 96 1 9 8 81.3%
Hb A1c Test 76 75 1 2 1 89.9%
Poorly Controlled 27 27 0 1 1 94.8%
Total 103 102 1 3 2 94.6%
Hb A1c Test 35 33 2 2 0 92.5%
Poorly Controlled 25 27 -2 0 2 92.8%
Total 60 60 0 2 2 92.8%
Hb A1c Test 42 41 1 2 1 92.9%
Poorly Controlled 46 47 -1 1 2 92.8%
Total 88 88 0 3 3 92.8%
Hb A1c Test 40 33 7 7 0 71.0%
Poorly Controlled 16 23 -7 0 7 72.4%
Total 56 56 0 7 7 74.0%
Hb A1c Test 58 58 0 0 0 100.0%
Poorly Controlled 33 33 0 0 0 100.0%
Total 91 91 0 0 0 100.0%
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Table 7
PHP/Community 
Connection
Critical Errors % Kappa 
Agreement
Maricopa Health 
Plan
Original 
Abstraction
AHCCCS 
Results Difference
Pinal/Gila LTC
Mercy Care LTC
DES/DDD
Pima LTC
Maricopa LTC
Yavapai LTC
AHCCCS Diabetes Management Performance Improvement Project
First Remeasurement Period: October 1, 2002, through September 30, 2003
DATA VALIDATION RESULTS, BY CONTRACTOR
Evercare Select
Mercy Care Plan
University 
Family Care
Health Choice 
Arizona
Cochise LTC
Pima Health 
System
APIPA
Over Under
Hb A1c Test 77 76 1 1 0 96.8%
Poorly Controlled 29 28 1 1 0 97.5%
Total 106 104 2 2 0 97.9%
Critical Errors % Kappa 
Agreement
AHCCCS 
Results
TABLE 8
AHCCCS Diabetes Management Performance Improvement Project
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Health Choice 
Arizona
Original 
Abstraction
Data Validation Results, Health Choice Arizona
Second Remeasurement Period: October 1, 2003, through September 30, 2004
Difference
Table 8 
Contractor Interventions to Improve Performance in Diabetes Management 
The following table includes interventions that AHCCCS Contractors used to improve rates of Hb A1c testing and levels during this PIP. 
The Chronic Care Model, developed by Wagner, et al, was adapted for use in organizing these interventions. The model identifies 
essential elements of a health care system that encourage high-quality care, and help ensure increased use of or access to services.1  
 
Community 
Linkages Health System  
Self-Management 
Support 
Delivery System 
Design Decision Support 
Clinical 
Information 
Systems 
Tie in outreach 
efforts with related 
activities/events; 
e.g., National 
Diabetes 
Awareness, 
community health 
fairs, etc.; may 
include partnering 
with another 
organization to 
provide free 
glucose testing 
 
Participate in the 
Arizona Diabetes 
Collaborative 
(2003-2004) to 
enhance 
knowledge and 
identify additional 
resources for 
diabetes care 
 
Share goals of the 
Diabetes PIP and 
specific health plan 
results with provider 
network to engage 
them as 
stakeholders 
 
Incorporate 
performance goals 
into provider 
contracts, including 
Primary Care 
Providers (PCPs), 
as well as LTC 
providers such as 
assisted living 
facilities and 
attendant care 
providers; may 
involve ”pay-for- 
performance” 
rewards 
 
 
 
Case management 
or disease 
management staff 
follow up with 
patients to provide 
education, referral 
to diabetes classes 
and/or assistance 
in obtaining 
services (e.g., 
transportation to 
appointment, 
obtain lab order 
from PCP and  
schedule blood 
draw) 
 
Use of diabetes 
educators and 
group classes to 
help members 
better understand 
and participate in 
managing their 
disease 
Utilize in-home Hb 
A1c testing kits, 
administered by case 
managers or home 
health nurses, for 
some long-term care 
members 
 
Identify members 
with diabetes 
through regular 
reports, such as 
claims or 
laboratory data, 
and new member 
health risk 
assessments 
 
Stratify members 
by risk (high, 
moderate, low) 
and prioritize for 
intervention based 
on level of risk 
(mail, telephone 
outreach, home 
health visit, etc.) 
 
Develop and send 
provider utilization 
profiles of services 
received by 
diabetic patients 
on a PCP’s panel 
Use administrative 
data (e.g., claims) 
to routinely monitor 
performance/ 
utilization of 
services overall and 
by provider 
 
Incorporate medical  
chart audits into the 
performance 
monitoring process, 
with feedback to 
providers and 
facilities 
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Community 
Linkages Health System  
Self-Management 
Support 
Delivery System 
Design Decision Support 
Clinical 
Information 
Systems 
    Incorporate data
reporting 
requirements into 
laboratory contracts 
to improve 
performance 
monitoring 
  Reinforce 
education/self- 
management skills 
through 
newsletters, 
special mailings, 
disease 
management 
information on 
website, etc 
 
 
Send letters or 
make phone calls 
to providers to 
advise them of 
their patients who 
have no or 
elevated Hb A1c 
results on record, 
or who have not 
refilled diabetic 
medications, so 
provider can 
engage patients 
 
Develop/adopt
practice guidelines 
and distribute to 
PCPs (physicians, 
PAs, NPs); 
reinforce through 
provider 
newsletters and 
other 
communications 
 
Implement use of 
tools, such as a 
diabetes flow 
sheet placed in the 
chart, by physician 
offices or facilities 
(e.g., nursing 
facilities) to prompt 
performing tests 
 
Provide continuing 
education on 
diabetes care to 
providers and 
health plan case 
managers 
 
 
 
1 Improving Chronic Illness Care. Overview of the Chronic Care Model.  Available at: 
http://www.improvingchroniccare.org/change/model/components.html 
 
 24
Arizona Health Care Cost Containment System (AHCCCS) 
PERFORMANCE IMPROVEMENT PROJECT (PIP): 
 
Improving Hb A1c Testing and Levels among Members with Diabetes 
 
METHODOLOGY 
 
Background 
The United States Department of Health and Human Services estimates that almost 20 
million Americans age 20 years and older have diabetes.1,2   Direct and indirect costs 
associated with diabetes in the United States, including lost productivity, were estimated 
to be $132 billion in 2002.3 
 
Diabetes is the leading cause of end-stage kidney disease, lower extremity amputations, 
and new cases of blindness among U.S. adults ages 20 to 74 years.4 Other complications 
of diabetes include heart disease, stroke, high blood pressure, nervous system damage, 
and dental disease. People with diabetes are more susceptible to many other illnesses; for 
example, they are more likely to die from pneumonia or influenza than people who do not 
have diabetes.1 
 
Control of hyperglycemia (increased blood sugar) is critical to preventing or minimizing 
complications of diabetes. Sustained high blood sugars result in damage to the retina, 
peripheral nerves and kidneys. Thus, preventive-care practices, such as monitoring of 
blood-glucose levels, are effective in reducing both the incidence and progression of 
diabetes-specific complications. 
 
Physicians utilize a glycosylated (also called glycated) hemoglobin, or Hb A1c, test to 
monitor patients’ blood glucose levels. This test provides an indication of a person’s 
average glucose levels over a two- to three-month period by measuring the amount of 
glucose that has bonded with hemoglobin in the body’s red blood cells. A normal Hb A1c 
level for persons without diabetes is between 4 and 6 percent.5
 
Purpose 
The purpose of this performance improvement project (PIP) is to increase the rate of Hb 
A1c testing among adults with diabetes who are enrolled with the Arizona Health Care 
Cost Containment System (AHCCCS), in order to assist those members and their 
physicians with establishing and maintaining control of blood-glucose (glycemic) levels.  
 
It is expected that interventions related to this project will increase the number of 
AHCCCS Contractors that meet or exceed the NCQA benchmark for Medicaid managed-
care plans.  
 
Measurement. Periods 
Baseline Measurement: October 1, 2000, through September 30, 2001 
First Remeasurement:  October 1, 2002, through September 30, 2003 
Second Remeasurement: October 1, 2003, through September 30, 2004 
 i
Study Questions 
1. What is the number and percent, overall and by Contractor, of members enrolled with 
AHCCCS who meet the sample frame criteria and who had at least one Hb A1c test? 
2. What is the number and percent, overall and by Contractor, of members enrolled with 
AHCCCS who meet the sample frame criteria and who had Hb A1c levels greater than 
9.5 percent? 
3. Of those members who had at least one HB A1c test during the measurement period, 
what is the median level of the most recent test? 
 
Population 
This study will include AHCCCS members diagnosed with diabetes, as defined by 
HEDIS criteria. Members may be identified as diabetic during the measurement year or 
twelve months prior. 
  
Population Exclusions 
The following members will be excluded from this study: 
• Members with steroid induced diabetes and gestational diabetes 
• Members with a diagnosis of polycystic ovaries who do not have two face-to-face 
encounters with the diagnosis of diabetes in any setting during the measurement year 
or prior year 
• Tribal and Fee for Service members will be excluded due to the inability to accurately 
collect complete data on these populations.  
 
Population Stratification 
The population will be stratified by: 
• Program type (Acute-care, ALTCS* and DES/DDD*) 
• Contractor 
 
* E/PD and VD populations for each Contractor will be combined before stratifying 
 
Sample Frame 
The sample frame will consist of members 18 through 75 years of age as of the end of the 
measurement period who were continuously enrolled during the measurement period, 
with no more than one gap in enrollment of up to 31 days, and diagnosed with type 1 or 
type 2 diabetes. 
• Prior Period Coverage (PPC) will be considered a break in enrollment. 
• A change of county service area with the same Contractor, without a gap in 
enrollment, will not be considered a break in enrollment. 
 
Sample Selection 
The sample frame will be identified through enrollment, claims and encounter records 
using the stated criteria. A statistical software program will be used to select a 
representative, random sample, using a 95-percent confidence level and a confidence 
interval of +/-5 percent. Based on prior studies, an over sampling rate of 10 percent will 
be utilized to allow for missing or incomplete records. 
 ii
Identification of Members with Diabetes 
Members with diabetes will be identified, according to HEDIS specifications, by one of 
the following methods: 
 
Pharmacy Data 
• National Drug Code (NDC) list available at: 
http://www.ncqa.org/Programs/HEDIS/hedis2004NDClists.htm 
OR 
Diagnosis Codes 
• 250      – Diabetes mellitus 
• 357.2   – Polyneuropathy in diabetes 
• 362.0   – Diabetic retinopathy 
• 366.41 – Central serous retinopathy 
• 648.0   – Diabetes 
 
  AND 
 
Two face-to-face encounters with different dates of service in an ambulatory or non-acute 
inpatient setting, or one face-to-face encounter in an acute inpatient or emergency room 
setting during the measurement year, or the year prior to the measurement year, with a 
diagnosis of diabetes as specified above. See Appendix A for codes to identify 
encounters. 
 
Indicators 
Hb A1c testing 
This indicator measures whether selected members received one or more Hb A1c tests 
during the measurement period, identified through either administrative data or medical 
record review. A member is considered to have had an Hb A1c test if: 
• a claim or encounter with CPT code 83036 (glycated hemoglobin laboratory test) or 
an automated laboratory record with a service date during the measurement period 
was found for the member, or 
• there was documentation in the member’s medical record (at a minimum, a note or 
lab result record) indicating the date an Hb A1c test was performed and the result. 
The following notations count toward this indicator: 
o glycated hemoglobin 
o glycosylated hemoglobin 
o A1c 
o Glycohemoglobin A1c 
o HbA1c 
o Hemoglobin A1c 
o HgbA1c 
 
Poor Hb A1c Control 
This indicator measures the degree of blood-glucose control of members, and is defined 
as “poor” if: 
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• the most recent Hb A1c level performed during the measurement period was greater 
than 9.5  percent, as documented through automated laboratory data or medical record 
review, or 
• there was no Hb A1c test performed during the measurement period or no Hb A1c 
level documented. 
 
Note: Glycosylated hemoglobin or glycohemoglobin may be converted to Hb A1c using 
the following formula: (0.685 glycohemoglobin) + (1.2) = Hb A1c. 
 
Controlled Hb A1c 
Blood glucose is considered “controlled” if the most recent Hb A1c test performed during 
the measurement period shows a level less than or equal to 9.5 percent, as documented 
through automated laboratory data or medical record review. 
 
Denominators 
1. The total number of sample members enrolled with AHCCCS Contractors 
 
Numerators 
1. The number of members who had one or more Hb A1c tests during the measurement 
period 
2. The number of members whose most recent Hb A1c levels were greater than 9.5 
percent or who did not have Hb A1c tests during the measurement period 
 
Confidentiality Plan 
AHCCCS continues to work in collaboration with Contractors to maintain compliance 
with the Health Insurance Portability and Accountability Act (HIPAA) requirements. The 
Data Analysis and Research (DAR) Unit maintains the following security and 
confidentiality protocols: 
• To prevent unauthorized access, the sample member file is maintained on a secure, 
password-protected computer, by the DAR project lead. 
• Only AHCCCS employees who analyze data for this project will have access to study 
data. 
• All employees and Contractors are required to sign a confidentiality agreement. 
• Requested data are used only for the purpose of performing health care operations, 
oversight of the health care system, or research. 
• Only the minimum amount of necessary information to complete the project is sent to 
and returned from Contractors. 
• Sample files given to Contractors are tracked to ensure that all records are returned. 
• Member names are never identified or used in reporting. 
• Upon completion, all study information is removed from the computer and placed on 
a compact disk, and stored in a secure location. 
 
Data Sources 
• Encounters, claims and pharmacy data (Form C) will be used to identify the 
population. 
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• AHCCCS has worked in collaboration with laboratories to establish a direct data links 
between Contractors and laboratories in their networks. These laboratories have the 
capability to electronically download member lab results directly into a Contractor’s data 
information system. Contractors may collect data directly from their data information 
systems.  
• When administrative or laboratory data is not available, data will be collected from 
members’ medical or case management records. A record of a claim paid by the 
Contractor for an Hb A1c test (CPT code 83036) with the date of service also may be 
used for the indicator of Hb A1c testing in the event that no other data source is available. 
 
Data Collection Tool 
A data collection tool was developed specifically for this study by the DAR Unit for the 
baseline measurement. A copy of the blank tool in electronic form was provided to each 
Contractor for optional use in collecting data. This tool is designed to collect accurate 
data in a simple and concise manner, while maintaining member confidentiality in 
compliance with HIPAA guidelines. 
 
An electronic file of sample members with instructions will be provided to each 
Contractor for data entry. 
 
Data Collection Process 
• When the final population file is received from the AHCCCS Information Services 
Division, the sample population will be stratified and selected by the DAR Unit. An 
electronic data file will be prepared for each Contractor 
• Contractors will collect the required data and enter it on the electronic file. 
• The electronic data file will then be returned to AHCCCS. 
 
Quality Assurance Process 
• Contractors will be instructed in use of the data collection tool, data collection 
methods, sample file layout and timelines for data collection during a meeting with 
AHCCCS staff. 
• Contractors will receive written instructions for data collection, in addition to 
AHCCCS resource and contact information for assistance. 
• AHCCCS will verify that all records have been returned. Distribution to Contractors 
and return of sample files will be monitored by the DAR Unit. 
 
Data Validation 
• To verify Hb A1c level, Contractors must submit any one of the following for each 
member identified as having an Hb A1c test: laboratory records, pertinent medical or 
case management record(s), or information extracted from direct transmission of 
laboratory data. 
• This documentation must contain the date of service and the Hb A1c level. Thus, the 
documentation also will validate that an Hb A1c test was performed during the 
measurement period. 
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• If no documentation of an Hb A1c level is available, but the Contractor has evidence 
of a claim paid for an Hb A1c test (CPT code 83036), the Contractor should submit 
verification of the administrative data. 
• A double-blind validation will be performed by AHCCCS, matching the medical/case 
management record or laboratory data with data on the Contractor’s electronic file. 
 
Limitations 
• A large portion of the ALTCS population also is covered by Medicare and seeks 
services outside the AHCCCS provider system.  Because Medicare is the primary payer 
for Medicare beneficiaries, AHCCCS and/or it health plans may not have the ability to 
collect information on services provided to members outside the AHCCCS system. Thus, 
some members with diabetes may not be identified for inclusion in the denominator or 
the numerator.  
 
Deviations from Previous Methodology 
• Codes to identify diabetic members were updated in HEDIS® 2004, including: 
o CPT codes 99289 and 99290 were deleted from the Outpatient/Nonacute 
Inpatient.  
o DRG code 205 was deleted from Diabetes diagnosis and replaced with 
DRG code 295 
o Add DRG code 294 to identify Diabetes 
o Add UB-92 Revenue Code 0456. (this code replaced DRG code 462  
o UB-92 Revenue codes 45X were deleted from Acute Inpatient/Emergency 
Department and replaced with codes 0450,0451,0452, and 0459. 
 
• Plans should have documentation of the lab vendor’s conversion formula available 
for the HEDIS Compliance Auditor.  NCQA will recommend removing glycohemoglobin 
tests from the specifications during the HEDIS 2005 public comment period. 
 
Analysis Plan 
• The denominator will be divided by the numerator to determine the percentage of 
compliance with each indicator. The rates will be analyzed and reported by program 
(ALTCS, Acute-care and DES/DDD), individual Contractor, urban and rural 
counties, and statewide aggregate. 
• The median of the most recent laboratory values of all members who had an HB A1c 
test during the measurement period will be calculated and reported overall, by 
program and by individual Contractor 
• Variability of distribution will be calculated by range and standard deviation. Any 
Contractor with results more than two standard deviations from the mean will be 
identified, and the reason ascertained if possible.  To avoid skewed and misleading 
conclusions, any such Contractor may be excluded from selected charts and graphs.  
Clear documentation in the report will caveat any Contractor exclusions and the 
reasons for exclusion. 
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Comparative Analysis 
• Differences between the first remeasurement results and this second remeasurement 
will be analyzed for statistical significance and relative change. 
• The results of this study will be compared to the results of other state Medicaid 
programs as reported by the National Committee for Quality Assurance (NCQA).  
• Results for urban and rural counties will be compared. 
• Individual Contractors will be compared to each other and to the statewide average. 
• All other stratifications as deemed appropriate (i.e. age, gender) will be compared 
with each other. 
 
Report Format: 
• The report will include the methodology used, narrative summary of analysis 
findings, limitations and recommendations  
• Findings will be displayed in appropriate charts, tables and/or graphs, with results 
reported by individual Contractor, program type, and statewide aggregate. 
• The comprehensive findings will be presented in a manner that will allow for easy 
interpretation of the data by evaluators at the federal, state, and Contractor levels. 
• Results will be reported on the AHCCCS website and may be sent to organizations 
such as NCQA. 
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APPENDIX A 
 
Diagnosis, Procedure, and Revenue Codes 
ICD-9 CM Codes - UB 82/92 
 
Diabetes Mellitus members with the following codes will NOT qualify for the study: 
• 251.8 – Other specified disorders of pancreatic internal secretion 
• 256.4 – Polycystic Ovaries  
• 648.8x –Gestational diabetes 
• 962.0 –  Adrenal cortical steroids 
 
Diabetes Mellitus members with the following codes WILL qualify for the study: 
• 250    – Diabetes Mellitus without mention of complications 
• 357.2 – Polyneuropathy in diabetes 
• 362.0 – Diabetic retinopathy 
• 366.41 – Diabetic cataract 
• 648.0  – Diabetes Mellitus (classifiable to 250) 
 
GROUP I – CODES 
In conjunction with Revenue Codes – UB82/92  (Out-patient or Non-Acute Care) 
• 0456 Emergency Room – Urgent Care  
• 049x Ambulatory Surgical Care 
• 050x Outpatient Services 
• 051x Clinic 
• 052x Free-Standing Clinic 
• 053x Osteopathic Services 
• 055x Skilled Nursing 
• 056x Medical Social Services 
• 057x Home Health – Home Health Aide 
• 058x Home Health – Other Visits 
• 059x Home Health – Units of Service 
• 065x Hospice Service 
• 066x Respite Care (HHA only) 
• 076x Treatment /Observation Room 
• 077x Preventative Care Services 
• 082x Hemodialysis – Outpatient or Home 
• 083x Peritoneal Dialysis – Outpatient or Home 
• 084x Continuous Ambulatory Peritoneal Dialysis (CAPD) – Outpatient or 
Home 
• 085x Continuous Cycling Peritoneal Dialysis (CCPD) – Outpatient or Home 
• 088x Miscellaneous Dialysis 
• 092x Other Diagnostic Services 
• 094x Other Therapeutic Services 
• 096x Professional Fees 
• 0972 Professional Fees:  Radiology  - Diagnostic 
• 0973 Professional Fees:  Radiology – Therapeutic 
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• 0974 Professional Fees:  Radiology – Nuclear Medicine 
• 0975 Professional Fees:  Operating Room 
• 0976 Professional Fees:  Respiratory Therapy 
• 0977 Professional Fees:  Physical Therapy 
• 0978 Professional Fees:  Occupational Therapy 
• 0979 Professional Fees:  Speech Pathology 
• 0982 Outpatient Services 
• 0983 Clinic 
• 0984 Medical Social Services 
• 0985 EKG 
• 0986 EEG 
• 0988 Consultation 
• 0989 Professional Fees:  Private Duty Nurse 
 
AND/OR 
 
GROUP 1 CODES 
In conjunction with CPT Codes  - HCFA 1500 (Outpatient or Non-Acute Care)  
• 92002 – 92014 General Ophthalmological Services (New & Established 
Patient) 
• 99201 – 99205  New Patient:  Office or other outpatient visit 
• 99211 – 99215 Established Patient: Office or other outpatient visit 
• 99217 – 99220     Observation Care Discharge Services and Initial Observation & Care 
(New or Established Patients. 
• 99241 – 99245 Office or Other Outpatient Consultations (New or Established 
Patient) 
• 99271 – 99275 Confirmatory Consultations  (New or Established Patient) 
• 99301 – 99303 Evaluation and Management (New or Established Patient) 
• 99311 – 99313 Subsequent Nursing Facility Care (New or Established Patient) 
• 99321 – 99323 Domiciliary Rest Home or Custodial Care Services (New 
Patients)  
• 99331  - 99333 Domiciliary Rest Home or Custodial Care Services 
(Established Patient) 
• 99341 – 99355 Home Services & Prolonged Services (New or Established 
Patient) 
• 99384 – 99387 Preventative Medicine (New Patient) 
• 99394 – 99397 Preventative Medicine (Established Patient) 
• 99401 – 99404 Preventative Medicine, Individual Counseling 
• 99411  Preventative Medicine, Group Counseling (30 minutes) 
• 99412 Preventative Medicine, Group Counseling (approx. 60 minutes) 
• 99420 – 99429 Other Preventative Medicine Services 
• 99499 Other Evaluation and Management Services 
 
AND/OR 
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GROUP 2 CODES 
In conjunction with Revenue Codes – UB82/92  (Acute-Inpatient or Emergency 
Department) 
• 010x All Inclusive Rate 
• 011x Room & Board – Private (Medical or General) 
• 012x Room & Board – Semi-Private Two Bed (Medical or General) 
• 013x Room & Board – Semi-Private – Three & Four Beds 
• 014x Room & Board – Private (Deluxe) 
• 015x Room & Board – Ward (Medical or General) 
• 016x Room & Board - Other 
• 020x Intensive Care 
• 021x Coronary Care 
• 022x Special Charges 
• 0450 Emergency Room – General Classification 
• 0451 Emergency Room – EMTALA Emergency Medical Screening Services 
• 0452 Emergency Room – ER Beyond EMTALA Screening 
• 0459 Emergency Room – Other Emergency Room 
• 072x Labor Room/Delivery 
• 080x Inpatient Renal Dialysis 
• 0981 Professional Fees – Emergency Room 
• 0987 Professional Fees – Hospital Visit  
 
GROUP 2 CODES 
In conjunction with CPT Codes  - HCFA 1500 (Acute Inpatient/Emergency 
Department) 
• 99221 – 99223 Initial Hospital Care (New or Established Patient) 
• 99231 – 99233 Subsequent Hospital Care 
• 99238 – 99239 Hospital Discharge Services 
• 99251 – 99255 Initial Inpatient Consultations (New or Established Patient)  
• 99261 – 99263 Follow-Up Inpatient Consultations (Established Patient) 
• 99281 – 99288 Emergency Department Services and Physician Direction 
• 99291 – 99292 Critical Care Services 
• 99356 - 99357 Prolonged Physician Service - Inpatient Setting* 
*MCOs should exclude women with gestational diabetes. 
 
GROUP 3 CODES 
Codes used to identify Diabetics using Pharmacy Data (Form C) (Therapeutic 
Class): 
Anti-Diabetic Agents  
• 682000 
Insulin 
• 682008 
Sulfonglurea 
• 682020 
Miscellaneous Active Agents 
• 682092 
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LAYOUT OF MEMBER IDENTIFIER FILE 
Below is the layout of the data file provided in your packet.  The file contains the demographic 
information for members included in the PIP study sample population.  This information is 
provided in both a d-BASE IV and an Excel spreadsheet format. 
Variable Variable Name Format Length 
1 AHCCCS Identification Text 9 
2 Health Plan Identification Number Text 6 
3 LName Text 30 
4 FName Text 20 
5 MI Text 3 
6 Gender Text 3 
7 DOB (MM/DD/YYYY) Date 10 
8 Age Text 3 
9 Hb A1c Test Text 3 
10 Gestational Diabetes Text 3 
11 Steroid Induced Diabetes Text 3 
12 Hb A1c Level Text 4 
13 Hb A1c Date Date 10 
14 Exclusion Reason Text 50 
 
 
Description of Included Elements 
AHCCCS Identification  9-digit AHCCCS member ID number 
Health Plan Identification 6-digit Contractor ID number 
LName Last name of the member as listed in the AHCCCS system 
FName First name of the member as listed in the AHCCCS system 
MI Middle Initial of the member as listed in the AHCCCS system 
Gender Gender of the member as listed in the AHCCCS system 
DOB Member date of birth as listed in the AHCCCS system 
Age  Age of member at the end of the study period 
Hb A1c Test Hb A1c test was or was not performed 
Gestational Diabetes Member has or does not have gestational diabetes 
Steroid Induced Diabetes Member has or does not have steroid induced diabetes 
Hb A1c Level Results of the latest Hb A1c level 
Hb A1c Date Date that latest Hb A1c test was completed  
Exclusion Reason Reasons why Hb A1c data was not provided 
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INSTRUCTION FOR CONSTRUCTING FILES 
 
 
Contractors mayn submit information in one of three ways: using an Excel 
spreadsheet provided by AHCCCS, or a d-BASE IV file or a Text file. The data 
layout and instructions described must be followed for submission to ensure 
accuracy of data translation and acceptance of data elements by AHCCCS. 
 
• All variable fields must be left justified. 
 
• All variable fields are to be used exactly as indicated in the above tables.   
 
• If information does NOT exist for any variable field, leave blank spaces in the 
columns. 
 
• Do not add any “new” variables that are not listed in the above table. 
 
• Do not change variable names. 
 
• Do not change the order of the variable fields. 
 
• Do not change any information provided by AHCCCS.  If there is a question 
regarding the information provided, please notify AHCCCS immediately. 
 
• A blank data collection tool, in a Word format will be provided for Contractor’s use 
only.  This tool is NOT to be returned with electronic data file.  
 
• All dates should be formatted as mm/dd/yyyy.  Thus, January 2, 2003 would be 
reported as 01/02/2003. 
 
• If submitting information in an Excel spreadsheet, use the file provided by AHCCCS.  
Do not change the formatting.  The format has been designed for accurate importing of 
the data into AHCCCS software.  Any changes to the format could result in lost 
information and a request for the Contractor to resubmit the data. 
 
• If submitting the information in a d-BASE IV format, use the field layout provided 
above.  If no information exists for a variable field or your data does not fill the required 
field length, use blank spaces in that column. 
 
• Data files must be formatted as fixed-width text files (*.txt). 
 
• Submit the data files using a 3.5” IBM compatible diskette or CD-ROM.  If file size 
is an issue, please compress the files into a .zip file.  If this does not solve the file size 
problem, please call Yvette McCormack at (602) 417- 4503. 
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• Put an external label on the disk or CD indicating: 
 
Health Plan or Program Contractor Name 
Contact Name & Phone Number 
Number of records in file(s) being provided 
 
• Send the disk or CD to: 
 
AHCCCS 
C/O Yvette McCormack - DAR 
701 East Jefferson, Mail Drop 6600 
Phoenix, AZ  85034 
 
ANY DEVIATIONS FROM THE INSTRUCTIONS FOR SUBMISSION OF DATA 
WILL NOT BE ACCEPTED AND RETURNED TO THE CONTRACTOR. 
 
Contact information: 
 
Technical questions related to the data request: should be directed to Yvette McCormack 
at (602) 417-4503 or e-mail:  yvette.mccormack@azahcccs.gov 
 
All other questions related to the project should be directed to Rochelle Tigner at (602) 
417-4683 or e-mail:  rochelle.tigner@azahcccs.gov 
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